Table 1.
The association of high body mass index with melanoma treatment.
| Reference | Cohort BMI kg/m2 | Immunotherapy | Targeted Therapy | Chemotherapy |
|---|---|---|---|---|
| [13] | Normal: <25 Obese: >30 |
Improved PFS and OS in obese melanoma cohort. Improved PFS and OS in male obese patients. No association in female obese patients. (ipilimumab, pembrolizumab, nivolumab, or atezolizumab) |
Improved PFS and OS in obese melanoma cohort. Improved PFS and OS in male obese patients. No association in female obese patients. (dabrafenib + trametinib and vemurafenib + cobimetinib) |
No association between BMI and clinical outcomes |
| [19] | Normal: 18.5–24.9 Overweight/obese: >25 | Improved PFS and OS in obese melanoma cohort (anti-PD-1/PD-L1 inhibitors) |
N/A | N/A |
| [123] | Normal: 18.5–25 Overweight/obese: 25–35 | Significantly higher response rate and a trend for longer OS in overweight/obese melanoma cohort (Ipilimumab) |
N/A | N/A |
| [21] | Normal/overweight: ˂30 Obese: ≥30 |
Improved PFS and OS in a cohort of obese advanced cancer patients including melanoma (anti-PD-1/PD-L1 inhibitors) |
N/A | N/A |
| [18] | Normal: 18.5–25 Overweight/obese: 25–35 | Improved PFS and OS in overweight/obese melanoma cohort. Association was predominantly driven by males (pembrolizumab, nivolumab, or nivolumab plus ipilimumab) |
N/A | N/A |
Abbreviations: BMI, body mass index. PFS, Progression free survival. OS, Overall survival. PD-1, Programmed cell death protein 1. PD-L1, Programmed death-ligand 1. N/A, not applicable.